The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
第2型糖尿病管理的演變:使用SGLT-2抑制劑和GLP-1受體激動劑進行血糖控制及更多。
J Osteopath Med 2024-02-26
Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists.
抗發炎和抗氧化:開啟 SGLT2 抑制劑和 GLP1 受體激動劑心血管潛力的關鍵。
Antioxidants (Basel) 2024-01-28
Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.
新型抗高血糖藥物在2型糖尿病心血管結果的比較:一項荟萃分析。
ESC Heart Fail 2024-02-29
Novel Therapeutics for Type 2 Diabetes Mellitus-A Look at the Past Decade and a Glimpse into the Future.
2型糖尿病的新療法 - 回顧過去十年並展望未來。
Biomedicines 2024-07-27
GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.
GLP-1 受體激動劑和 SGLT2 抑制劑降低血糖並減少心血管疾病及糖尿病腎病的風險。
J Am Board Fam Med 2024-08-14